Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Padmanabhan · SciRah

Researcher profile · Semantic Scholar

S. Padmanabhan

Share profile

S. Padmanabhan — researcher profile on SciRah

h-index: 27
Works: 124
Citations: 4,256

Most-cited papers

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
B. Coiffier, B. Pro, H. Prince, F. Foss +14 more
2012Journal of Clinical Oncology648 citations
Semantic Scholar
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
W. Wierda, T. Kipps, J. Mayer, S. Stilgenbauer +16 more
2010Journal of Clinical Oncology610 citations Open access
Semantic Scholar
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
A. Chanan-Khan, Kena C. Miller, L. Musial, D. Lawrence +13 more
2006Journal of Clinical Oncology439 citations
Semantic Scholar
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
R. Swords, K. Kelly, Peter G. Smith, J. Garnsey +8 more
2010Blood269 citations Open access
Semantic Scholar
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
W. Wierda, S. Padmanabhan, G. Chan, I. Gupta +2 more
2011Blood179 citations Open access
Semantic Scholar
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
I. Ghobrial, F. Hong, S. Padmanabhan, A. Badros +12 more
2010Journal of Clinical Oncology159 citations Open access
Semantic Scholar
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
I. Ghobrial, Wan-Ling Xie, S. Padmanabhan, A. Badros +13 more
2010American journal of hematology/oncology143 citations
Semantic Scholar
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
W. Wierda, T. Kipps, J. Durig, L. Griškevičius +13 more
2011Blood119 citations Open access
Semantic Scholar
High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy
S. Yao, P. McCarthy, Lauren M. Dunford, D. M. Roy +8 more
2008Bone Marrow Transplantation80 citations Open access
Semantic Scholar
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
K. Kelly, R. Swords, D. Mahalingam, S. Padmanabhan +1 more
2009Targeted oncology78 citations
Semantic Scholar
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
K. Kelly, J. Ecsedy, E. Medina, D. Mahalingam +4 more
2011Journal of Cellular and Molecular Medicine76 citations Open access
Semantic Scholar
Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis.
M. Battiwalla, Yi-Yuan Wu, R. Bajwa, M. Radović +7 more
2007Biology of Blood and Marrow Transplantation75 citations Open access
Semantic Scholar
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
Kevin R. Kelly, S. Nawrocki, Claudia M. Espitia, Meng-Kun Zhang +5 more
2012International Journal of Cancer53 citations Open access
Semantic Scholar
A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy
R. Swords, J. Anguita, Russell A. Higgins, Andrea Yunes +10 more
2011Journal of Clinical Pathology51 citations
Semantic Scholar
Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial
A. Österborg, T. Kipps, J. Mayer, S. Stilgenbauer +16 more
200850 citations
Semantic Scholar
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
A. Chanan-Khan, Kena C. Miller, D. Lawrence, S. Padmanabhan +6 more
2012Cancer49 citations Open access
Semantic Scholar
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
H. Kantarjian, S. Padmanabhan, W. Stock, M. Tallman +13 more
2011Investigational new drugs49 citations Open access
Semantic Scholar
Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy
B. Coiffier, B. Pro, H. Prince, F. Foss +13 more
201049 citations
Semantic Scholar
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
H. Bansal, S. Bansal, M. Rao, K. Foley +13 more
2010Blood48 citations Open access
Semantic Scholar
Targeting aurora kinases in cancer treatment.
K. Kelly, J. Ecsedy, D. Mahalingam, S. Nawrocki +3 more
2011Current Drug Targets47 citations
Semantic Scholar
Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.
W. Wierda, T. Kipps, J. Durig, L. Griškevičius +14 more
200946 citations
Semantic Scholar
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
R. Swords, D. Mahalingam, S. Padmanabhan, J. Carew +1 more
2009Drug Design, Development and Therapy33 citations Open access
Semantic Scholar
A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)
M. Andreeff, K. Kojima, S. Padmanabhan, R. Strair +9 more
201030 citations
Semantic Scholar
Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence.
M. Battiwalla, T. Hahn, M. Radović, Hilary N. Roy +7 more
2006Blood28 citations
Semantic Scholar
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
D. Benson, C. Hofmeister, S. Padmanabhan, A. Suvannasankha +8 more
2012Blood27 citations Open access
Semantic Scholar
Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
W. Wierda, T. Kipps, J. Mayer, T. Robak +16 more
201025 citations
Semantic Scholar
Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients.
A. Chanan-Khan, M. Czuczman, S. Padmanabhan, M. Keating +3 more
200725 citations
Semantic Scholar
Targeting PIM kinase activity significantly augments the efficacy of cytarabine
K. Kelly, Claudia M. Espitia, P. Taverna, G. Choy +4 more
2012British Journal of Haematology24 citations Open access
Semantic Scholar
Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma
M. Benekli, S. Smiley, T. Younis, M. Czuczman +6 more
2008Bone Marrow Transplantation24 citations Open access
Semantic Scholar
Mammalian target of rapamycin as a target in hematological malignancies
K. Kelly, J. Rowe, S. Padmanabhan, S. Nawrocki +1 more
2011Targeted oncology23 citations
Semantic Scholar
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
A. Chanan-Khan, Kena C. Miller, L. Musial, S. Padmanabhan +10 more
2009Leukemia and Lymphoma23 citations
Semantic Scholar
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).
S. Padmanabhan, J. Beck, K. Kelly, N. Munshi +14 more
200922 citations
Semantic Scholar
Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study
B. Coiffier, A. Bosly, Ka-Lung Wu, G. Verhoef +12 more
201019 citations
Semantic Scholar
Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.
S. Horwitz, J. Vose, R. Advani, K. Sankhala +6 more
200919 citations
Semantic Scholar
Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.
M. O'Dwyer, E. Kent, M. Parker, R. Swords +8 more
200917 citations
Semantic Scholar
Chemoimmunotherapy with OFC in previously untreated patients with chronic lymphocytic leukemia
W. Wierda, T. Kipps, J. Durig, L. Griškevičius +13 more
201115 citations
Semantic Scholar
Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.
A. Ferrajoli, M. Keating, W. Wierda, S. O'Brien +3 more
200714 citations
Semantic Scholar
A comparison of races and leukemia subtypes among patients in different cancer survivorship phases.
D. Pandya, Sukeshi R. Patel, N. Ketchum, B. Pollock +1 more
2011Clinical Lymphoma, Myeloma & Leukemia13 citations
Semantic Scholar
Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias
I. Gojo, Alison R. Walker, Maureen A. Cooper, E. Feldman +7 more
201013 citations
Semantic Scholar
Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation.
Lauren M. Dunford, D. M. Roy, T. Hahn, S. Padmanabhan +4 more
2006Biology of Blood and Marrow Transplantation13 citations Open access
Semantic Scholar
Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.
Anna Beryozkina, G. Nichols, M. Reckner, L. Vassilev +16 more
2011Journal of Clinical Oncology11 citations
Semantic Scholar
Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.
A. Österborg, B. Rønn, R. Jewell, T. Kipps +19 more
200911 citations
Semantic Scholar
A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies.
S. Horwitz, J. Vose, R. Advani, K. Sankhala +11 more
200811 citations
Semantic Scholar
Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature
S. Padmanabhan, M. Battiwalla, T. Hahn, D. Ball +5 more
2007Transplant Infectious Disease11 citations
Semantic Scholar
Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.
S. Padmanabhan, T. Shea, J. Vose, C. Reeder +8 more
201010 citations
Semantic Scholar
Current status of therapy for chronic myeloid leukemia: a review of drug development.
S. Padmanabhan, Saritha Ravella, T. Curiel, F. Giles
2008Future Oncology10 citations
Semantic Scholar
A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,
C. Huff, S. Padmanabhan, K. Kelly, G. Somlo +7 more
20119 citations
Semantic Scholar
Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma
B. Coiffier, B. Pro, H. Prince, F. Foss +13 more
20118 citations
Semantic Scholar
A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia
E. Castillo, R. Al-Rajabi, D. Pandya, P. Varadarajan +5 more
20108 citations
Semantic Scholar
Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.
I. Ghobrial, F. Hong, S. Padmanabhan, A. Badros +12 more
20098 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Kelly×12
Invite
K. Kelly — researcher profile on SciRah
W. Wierda×10
Invite
W. Wierda — researcher profile on SciRah
F. Giles×10
Invite
F. Giles — researcher profile on SciRah
G. Chan×8
Invite
G. Chan — researcher profile on SciRah

×7

Invite

T. Kipps — researcher profile on SciRah

Invite

J. Mayer — researcher profile on SciRah

S. Stilgenbauer×7

Invite

S. Stilgenbauer — researcher profile on SciRah

Invite

R. Swords — researcher profile on SciRah

Invite

J. Carew — researcher profile on SciRah

M. Battiwalla×7

Invite

M. Battiwalla — researcher profile on SciRah

Invite

P. Hillmen — researcher profile on SciRah

Invite

C. Russell — researcher profile on SciRah